Betmiga貝坦利

Betmiga

mirabegron

Manufacturer:

Astellas

Distributor:

Firma Chun Cheong
/
DKSH
Concise Prescribing Info
Contents
Mirabegron
Indications/Uses
Symptomatic treatment of urgency, increased micturition frequency &/or urgency incontinence as may occur in adults w/ overactive bladder (OAB) syndrome.
Dosage/Direction for Use
Adult including elderly 50 mg once daily.
Administration
May be taken with or without food: Swallow whole, do not chew/divide/crush.
Contraindications
Hypersensitivity; severe uncontrolled HTN.
Special Precautions
End-stage renal disease, severe renal impairment; severe hepatic impairment (Child-Pugh Class C) & moderate hepatic impairment (Child-Pugh Class B); periodic BP monitoring; history of QT prolongation or taking medicines known to prolong QT interval; bladder outlet obstruction or taking antimuscarinics medications for OAB. Pregnancy & lactation.
Adverse Reactions
UTI; tachycardia; nausea, constipation, diarrhoea; headache, dizziness.
Drug Interactions
In patients w/ mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors eg, itraconazole, ketoconazole, the recommended dose is 25 mg once daily. CYP3A/P-gp inducers decrease the plasma conc of mirabegron. Medicines w/ narrow therapeutic index & significantly metabolized by CYP2D6 eg, thioridazine, type 1C antiarrhythmics (eg, flecainide, propafenone) & TCAs (eg, imipramine, desipramine); individually dose-titrated CYP2D6 substrates. In combination w/ digoxin, the lowest dose for digoxin should be initially prescribed.
ATC Classification
G04BD12 - mirabegron ; Belongs to the class of urinary antispasmodics.
Presentation/Packing
Form
Betmiga OCAS tab 25 mg
Packing/Price
30's
Form
Betmiga OCAS tab 50 mg
Packing/Price
30's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in